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Abstract
The emergence and pandemic spread of a new strain of influenza A (H1N1) virus in 2009 resulted in a serious alarm in
clinical and public health services all over the world. One distinguishing feature of this new influenza pandemic was the
different profile of hospitalized patients compared to those from traditional seasonal influenza infections. Our goal was to
analyze sociodemographic and clinical factors associated to hospitalization following infection by influenza A(H1N1) virus.
We report the results of a Spanish nationwide study with laboratory confirmed infection by the new pandemic virus in a
case-control design based on hospitalized patients. The main risk factors for hospitalization of influenza A (H1N1) 2009 were
determined to be obesity (BMI$40, with an odds-ratio [OR] 14.27), hematological neoplasia (OR 10.71), chronic heart
disease, COPD (OR 5.16) and neurological disease, among the clinical conditions, whereas low education level and some
ethnic backgrounds (Gypsies and Amerinds) were the sociodemographic variables found associated to hospitalization. The
presence of any clinical condition of moderate risk almost triples the risk of hospitalization (OR 2.88) and high risk conditions
raise this value markedly (OR 6.43). The risk of hospitalization increased proportionally when for two (OR 2.08) or for three or
more (OR 4.86) risk factors were simultaneously present in the same patient. These findings should be considered when a
new influenza virus appears in the human population.
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Introduction
The emergence of a new viral strain of influenza A (H1N1) virus
in the spring of 2009 represented the first pandemics of the 21st
century [1,2]. The initial data about the infection were alarming,
with apparently high death rates in unusual age group, such as
infants and children rather than the elderly. This was explained by
lack of exposure to a previous H1N1 influenza A virus which was
replaced in 1957 by the H2N2 ‘Asian-flu’ strain [3]. Additionally,
alarming greater than expected number of serious infections, even
with fatal outcomes, were observed among people with no
apparent risk for serious infection by influenza virus when
compared with the usual profile of seasonal influenza epidemics
[4].
Compared to seasonal epidemics, new influenza pandemics
have been characterized by increased transmissibility, higher
mortality in young age groups, geographic variability, activity
peaks out of the cold season and more than one epidemic wave
[5]. As a result, health systems world-wide were stressed and,
frequently, overwhelmed by the demand at different settings:
primary care centers, emergency units, hospital wards and
intensive care units.
Spain was the first European country to report a case of
pandemic influenza [6] and the rapid adoption of control
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33139measures limited the initial wave of the epidemics to 735 cases [7].
Nevertheless, in light of initial reports on underlying clinical
conditions leading to severity of infection with the new influenza
virus and the need to analyze the effectiveness of the different
measures of control adopted by Spanish authorities, a multicenter
study was initiated to evaluate these and other factors during the
2009–2010 pandemic wave.
Most previous published reports have analyzed factors leading
to extreme severity, usually defined as death or need for admission
to emergency care units, of influenza infection [8–12] but, to our
knowledge, no study has compared hospitalized patients with
influenza-infected controls. In this context, and given that
pandemic influenza may represent global health risks, we have
analyzed which sociodemographic factors and clinical conditions
were associated to hospitalization of confirmed influenza A(H1N1)
2009 virus infected patients in Spain during the first eight months
of pandemic influenza.
Materials and Methods
Study design
A multicenter study utilizing matched case-controls was
conducted and included 36 hospitals and primary care centers
from seven Spanish regions (Andalusia, Basque Country, Catalo-
nia, Castile and Leon, Madrid, Navarra, and Valencian
Community). Cases and controls were recruited between July
2009 and February 2010. Sample size needed to detect a relative
risk (OR) of 1.5 and assuming a prevalence of the investigated
factors in outpatients of 0.15, a bilateral significance level a=0.05
and a power of b=0.80 was 654. using the criteria proposed by
Schlesselman [13]. The most conservative assumptions were
adopted and the estimated sample size was increased in 10% to
account for possible losses. This resulted in a target sample size of
720 for both cases and controls.
Selection of cases and controls
A case was defined as a patient admitted to hospital for .24 h
with RT-PCR confirmed infection by influenza A(H1N1) 2009
virus [14]. Controls were defined as non-hospitalized persons with
RT-PCR confirmed infection by the same pandemic virus and
were recruited among patients attending primary care centers.
Hospitalized cases excluded nosocomial infections (assigned by
onset of symptoms 48 h or more after admission to the hospital).
Non-hospitalized controls were matched to hospitalized cases by
age (63 years for patients under 18 y and 65 y for older patients),
province of residence and date of admission to the hospital (610
days).
Sociodemographic and pre-existing medical variables
For all the subjects included in the study the following
demographic and medical variables were obtained: age, sex,
ethnic group, education level, tobacco and alcohol use, pregnancy
(for women 15–49 y of age), pneumonia in the 2 previous years,
chronic obstructive pulmonary disease (COPD), asthma, heart
disease, renal insufficiency, diabetes, HIV infection, disabling
neurological disease, neoplasia, transplant, morbid obesity (body
mass index, BMI.40), treatment with systemic corticosteroids,
treatment with inhaled corticosteroids, treatment with antibiotics
in the 90 previous days and vaccination against pandemic and
seasonal influenza. The medical conditions, retrieved from the
patients’ medical records, were classified into two groups
according to severity [10] (Table 1). The remaining variables
were obtained from direct or phone interviews to the patients (or
their parents in the case of infants and children).
Statistical analyses
Bivariate comparisons for sociodemographic and clinical
variables were performed between cases and controls by means
of Pearson’s chi-square, for categorical variables, and Student’s t
tests, for normally-distributed continuous variables. Crude Odds
Ratios (OR) were estimated using the McNemar chi-square test.
To estimate the adjusted odds ratio (aOR) a multivariate analysis
using conditional logistic regression was performed including those
independent variables found to be associated with both the risk
factor and the hospitalization in the previous bivariate analyses. In
order to detect those variables that could be associated in the
multivariate setting but not in the bivariate one, two additional
strategies were carried out: full model (i.e. with all candidate
variables) and stepwise backward regression [15]. The interactions
between age groups (0–18 years, $18 years) and the history of
vaccination were analyzed by logistic regression. The analyses
were performed with SPSS version 18.
Ethics
All the information collected was treated as confidential, in strict
observance of legislation on observational studies and the
principles expressed in the Declaration of Helsinki. The study
was approved by the Ethics Committee of the hospitals involved.
Written informed consent was obtained from all patients or their
parents in the case of children (0–17 years).
Results
A total of 699 hospitalized and 703 non-hospitalized cases of
influenza A (H1N1) 2009 were included in the study. Slightly more
than half of them (55%) were recruited after November 16, when
the vaccination program with the pandemic vaccine was started in
Spain.
The most relevant social and demographic variables for both
groups are shown in Table 2. Non-Caucasian ethnic groups
(Gypsies, Amerinds and Arabian/North-Africans) were consider-
ably more frequently present among hospitalized than among non-
hospitalized cases, with crude OR ranging from 2.74 to 8.20.
Lower education level was significantly more frequent among
hospitalized patients (OR 0.34, 95% confidence interval [CI]
0.26–0.46). More women were present among non-hospitalized
than in hospitalized cases, but after adjustment for other variables
(Table S1) sex was no longer statistically significant. We
encountered some problems in applying the same matching
criterion (63 years) in the eldest age group (.65 years) than in the
other groups and, consequently, we had to increase the age
interval considered up to 5 years. This and the low number of non-
hospitalized cases among this age group explains the significant
difference found in the age group distributions, which disappeared
in the adjusted multivariate analysis (Table 2).
Differences between cases and control groups in the frequency
of most risk factors and clinical conditions were statistically
significant in the bivariate analyses (Table 3). Relevant exceptions
were pregnancy and alcoholism, which were not significant, and
renal disease, previous smoking habit and transplant, which were
almost significant (p=0.06). The presence of the condition was
associated to increased risk of hospitalization in all cases except for
pregnancy (OR 0.77, CI 0.41–1.45). However, a more detailed
analysis of this factor showed that pregnancy after week 30 was
actually associated to an increased risk of hospitalization (aOR
4.17, CI 1.32–13.18). An interaction between age (,18 and $18
years) and pandemic influenza vaccination was observed, and
therefore these two groups were considered separately. Coverage
with pandemic influenza vaccine was very low in both cases and
Hospitalization by Pandemic Influenza Infection
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differences between groups. , but the statistical power was only
2% for ,18 years and 3.8% for $18 years. No statistically
significant differences were observed between cases and controls
with regards to seasonal influenza vaccination. The statistical
power was also low, but higher than for pandemic vaccine (9.6%
for ,18 years and 59.3% for $18 years).
Using the two additional strategies to detect possible confound-
ers that were present in the multivariate setting but not in the
bivariate one, no additional confounders were found (results not
shown here but available upon request).
Adjusted multivariate analyses revealed that only a subset of the
previous variables were still significantly different between
hospitalized and non-hospitalized influenza patients (see Table
S1). Among the non-clinical variables (Table 2), the strongest
significant effect was found for the education level, with low levels
of education associated to hospitalization (aOR 0.44, CI 0.31–
0.63). Some ethnic backgrounds retained marginal significance, in
particular Gypsies (aOR 8.26, CI 1.03–66.34) and Amerinds (aOR
2.30, CI 1.16–4.58).
Multivariate analyses (Table 3) showed that the variables
associated with the highest risk of hospitalization were obesity
(aOR 14.27, CI 1.67–91.7), hematological neoplasia (aOR 10.71,
CI 1.95–58.87), chronic heart disease (aOR 6.1, CI 1.43–26.09),
COPD (aOR 5.16, CI 1.98–13.45), and disabling neurological
disease (aOR 4.0, CI 1.24–12.99). Congestive myocardiopathy
showed a high associated risk but without statistical significance
(aOR 7.31, CI 0.40–75.81), and the remaining clinical variables
retained only marginal statistical significance (0.05.p.0.01) and/
or represented a relatively low risk of hospitalization (aOR,3).
Finally, we have analyzed the global effect of risk factors. We
have used two different approaches. Firstly, we considered the
effect associated to the severity of risk factors by considering cases
with at least one moderate or severe risk actor (Table 1). The
effects were highly significant (p,0.001) for both categories with
higher risk for severe factors (aOR 6.43, CI 3.45–11.98) than for
moderate ones (aOR 2.88, CI 1.90–4.35). Secondly, we considered
the number of risk factors simultaneously present in each patient
regardless their severity. In this case, the higher the number of
factors the higher the risk of hospitalization, with an aOR=4.86
(CI 3.21–7.35) for three or more factors (Table 3).
Discussion
In this study, we have analyzed the factors associated with
increased risk of hospitalization among pandemic influenza virus
infected patients usinga case-controldesignwithparticipants from a
large data set of Spanish hospitals and primary health care centers.
ThemainriskfactorsforhospitalizationofinfluenzaA(H1N1)2009
were determined to be obesity (BMI$40), hematological neoplasia,
chronic heart disease, COPD and neurological disease, among the
clinical conditions, whereas low education level and some ethnic
backgrounds (Gypsies and Amerinds) were the sociodemographic
variables found associated to hospitalization.
Table 1. Medical conditions considered in this study classified according to severity [10].
Severity Medical conditions
High risk Solid organ neoplasia
Hematological neoplasia
Renal insufficiency requiring hemodialysis
Transplant
Asplenia
Oral corticosteroid therapy, doses .20 mg/day/15 days in the last month
Immunosuppressive therapy (chemotherapy or others)
Autoimmune disease
Nephritic syndrome
Disabling neurological disease or severe alteration of psychomotor development
AIDS
Moderate risk Asymptomatic HIV infection
Diabetes mellitus
Congestive or hemodynamically unstable congenital cardiomyopathy
COPD, defined as respiratory symptoms for longer than 3 months
Asthma
Chronic liver disease
Renal insufficiency not requiring hemodialysis
Hemoglobinopathy or anemia
Mental disability: Down syndrome, dementia and others
Neuromuscular disease
Convulsions
Long-lasting therapy with acetylsalicylic acid
Obesity (with MIC score)
Pregnancy
doi:10.1371/journal.pone.0033139.t001
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tion by pandemic influenza virus hospitalization has several salient
features. First, it is based on a case-control design; second, the
control group consisted of non-hospitalized, influenza-infected
patients matched by age group, date of hospitalization/symptoms
onset and residence, which allowed to minimize hidden effects of
confounding factors; and, finally, it included a relatively large
sample size (n=699 hospitalized and 703 non-hospitalized cases).
Case-control studies are among the most common designs in
epidemiological studies because of their merits in cost, effort and
yield [16]. However, only a few studies in the context of the new
pandemic influenza have used this design, mostly in analyses of
vaccine effectiveness [17–21]. Although a study comparing
hospitalized and outpatient cases of confirmed pandemic influenza
infection has been published recently [22], this is one of the first
studies comparing hospitalized pandemic influenza patients with a
control group of pandemic influenza infected patients who evolved
more favorably and did not require hospitalization. By using a
matched case-control design we have been able to analyze
specifically those variables leading to increased risk of hospitaliza-
tion in pandemic influenza infected patients after removal of other
confounding factors.
Most analyses of factors leading to hospitalization due to
pandemic influenza are observational studies on prospective or
retrospective cohorts [23–25]. Some studies have used the general
population as the control group [26–29] or the comparison has
been made to seasonal influenza-infected patients [30]. The choice
of control group is a key issue in the validity of case-control studies
[16]. We were interested in analyzing which factors influenced
hospitalization in people infected by the pandemic virus without
the possible confounding effects of susceptibility to infection. In
consequence, we have used non-hospitalized patients with the
same diagnostic criterion, age, location, and time of infection by
the pandemic virus than the matching case. Gilca et al. [22] also
used a case-control design with pandemic influenza virus-infected
patients to analyze factors associated to risk of hospitalization and
outcome severity. Some conclusions from this analysis differ from
those obtained in our study (see below), which might be explained
by differences in the studied populations but also in methodology
because Gilca et al. did not match cases and controls by age and
date of hospitalization as in this report.
Ethnicity has appeared associated to severity of infection by
pandemic influenza virus in several studies, with indigenous or
foreign groups having a larger risk of hospitalization than resident
or non-minority groups [31–37]. However, there is no evidence
for a biological or genetic basis for these differences [35] which
have been found also in previous epidemics and its significance,
along with that of the education level, may be attributed more to
social than biological causes. Access to health services is legally
granted to all the residents in Spain but this does not necessarily
mean in equal use of these services by all the groups. Immigration
and lower education level may be associated with a delay in
accessing the physician’s consult which, in turn, might aggravate
the clinical condition and lead to hospitalization.
The three main factors associated to increased risk of
hospitalization among infected patients were morbid obesity,
hematological neoplasia, and COPD, all of which had adjusted
ORs higher than 5. Two additional factors, chronic heart disease
and congestive cardiomyopathy, also had adjusted ORs larger
than 5, but their significance was much lower, 0.01 and 0.09,
respectively. Other risk factors identified in our analysis after
adjustment included diabetes, previous administration of systemic
corticosteroids, chronic respiratory distress, hypertension, previous
pneumonia, previous antibiotic treatment and asthma.
Table 2. Main sociodemographic features of hospitalized and non-hospitalized patients with confirmed infection by influenza
A(H1N1) 2009 virus in Spain 2009–2010.
Hospitalized cases
(n=699)
Non-hospitalized
cases (n=703) Crude OR (95% CI) p value Adjusted OR (95% CI) p value
Age average ± SD 37.82622.77 35.72620.77 1.08 (0.90–1.21) 0.07 1.05 (0.91–1.19) 0.07
Age group
0–4 79 (11.3%) 74 (10.5%) 1 1
5–14 76 (10.9%) 87 (12.4%) 0.45 (0.19–1.11) 0.08 0.25 (0.03–1.81) 0.17
15–24 57 (8.2%) 81 (11.5%) 0.53 (0.18–1.54) 0.24 0.38 (0.06–2.42) 0.31
25–44 203 (29.0%) 242 (34.4%) 1.04 (0.33–3.26) 0.95 0.53 (0.08–3.47) 0.50
45–65 197 (28.2%) 184 (26.2%) 3.10 (0.92–10.42) 0.08 0.91 (0.13–6.22) 0.92
$65 87 (12.4%) 35 (5.0%) 26.27(5.94–116.20) 0.001 6.73 (0.77–58.81) 0.08
Women 356 (50.9%) 399 (56.8%) 0.78 (0.63–0.97) 0.03 0.82 (0.61–1.12) 0.21
Ethnic group
White 602 (87.2%) 645 (93.6%) 1 1
Gypsy 15 (2.2%) 2 (0.3%) 8.20 (1.86–36.25) 0.006 8.26 (1.03–66.34) 0.04
Amerind 46 (6.7%) 17 (2.5%) 2.90 (1.630–05.17) ,0.001 2.30 (1.16–4.58) 0.02
Arabian or North-African 17 (2.5%) 6 (0.9%) 2.74 (1.08–6.96) 0.03 2.94 (0.86–10.02) 0.08
Other 10 (1.4%) 19 (2.8%) 0.65 (0.28–1.47) 0.30 0.98 (0.32–2.99) 0.98
Education level
Secondary or higher 381 (57.6%) 521 (77.0%) 0.34 (0.26–0.46) ,0.001 0.44 (0.31–0.63) ,0.001
Crude and adjusted odds-ratios, from bivariate and multivariate (logistic regression) analyses respectively, are shown. Only variables used in the adjusted analyses are
reported.
OR=Odds ratio; CI=Confidence interval.
doi:10.1371/journal.pone.0033139.t002
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hospitalization in our study. The same result was obtained by
Morgan et al. [27] in individuals .20 years (n=161) when
compared to the NHANES cohort. Among 2–19 year patients
(n=200), hospitalization was associated with being underweight
(BMI,=5th percentile). Morbid obesity was also found to be
associated with hospitalization by pandemic influenza [23,38–40]
but Vasoo et al. [41] and Gilca et al. [22] did not find obesity to be
a significant factor for hospitalization.
Asthma was found significantly more often in children
hospitalized in Canada with pandemic influenza than those
admitted to hospital due to seasonal influenza [30] and its
incidence among hospitalized patients was higher than in the
general population in Australia and New Zealand [31]. Asthma
Table 3. Main risk factors and clinical conditions of hospitalized and non-hospitalized patients with confirmed infection by
influenza A(H1N1) 2009 virus in Spain 2009–2010.
Hospitalized
cases (n=699)
Non-hospitalized
cases (n=703) Crude OR (95% CI) p value Adjusted OR (95% CI) p value
Smoking habits
Current smoker 112 (18.0%) 87 (14.8%) 1.44 (1.04–1.99) 0.03 1.06 (0.65–1.74) 0.81
Former smoker 149 (24.0%) 132 (22.4%) 1.32 (0.98–1.78) 0.06 1.12 (0.73–1.72) 0.59
Alcoholism 39 (5.7%) 25 (3.9%) 1.56 (0.93–2.64) 0.09 1.36 (0.69–2.69) 0.37
Pregnancy 46 (15.4%) 56 (18.2%) 0.77 (0.41–1.45) 0.37 1.12 (0.52–2.44) 0.77
Pneumonia in the 2 last years 73 (15.2%) 42 (6.1%) 3.38 (2.05–5.57) ,0.001 2.29 (1.08–4.84) 0.03
COPD 68 (9.8%) 12 (1.7%) 6.68 (3.43–12.99) ,0.001 5.16 (1.98–13.45) 0.001
Asthma 116 (16.7%) 79 (11.5%) 1.54 (1.13–2.10) 0.007 1.59 (1.12–2.28) 0.01
Chronic respiratory distress 53 (7.6%) 6 (0.9%) 10.37 (4.14–25.99) ,0.001 2.97 (1.02–8.70) 0.04
Hypertension 132 (19.2%) 71 (10.7%) 2.45 (1.70–3.53) ,0.001 2.52 (1.10–5.79) 0.03
Chronic heart disease 62 (9.0%) 14 (2.1%) 6.62 (3.15–13.93) ,0.001 6.10 (1.43–26.09) 0.01
Congestive cardiomyopathy 16 (3.4%) 3 (0.5%) 16.0 (2.12–120.65) 0.01 7.31 (0.70–75.81) 0.09
Renal insufficiency 29 (4.2%) 15 (2.3%) 1.93 (1.01–3.68) 0.04 1.87 (0.87–4.03) 0.11
Nephritic syndrome 11 (1.6%) 5 (0.8%) 1.75 (0.51–5.98) 0.37 0.60 (0.14–2.62) 0.50
Diabetes 86 (12.4%) 19 (2.9%) 6.00 (3.33–10.79) ,0.001 3.26 (1.09–9.80) 0.03
AIDS/HIV infection 16 (2.3%) 6 (0.9%) 2.42 (0.93–6.33) 0.07 1.31 (0.39–4.37) 0.66
Disabling neurological disease 31 (4.5%) 11 (1.7%) 2.80 (1.36–5.76) 0.01 4.00 (1.24–12.99) 0.02
Solid organ neoplasia 35 (5.1%) 18 (2.7%) 1.94 (1.06–3.54) 0.03 1.92 (0.99–3.73) 0.06
Hematological neoplasia 25 (3.6%) 7 (1.1%) 3.00 (1.27–7.06) 0.01 10.71 (1.95–58.87) 0.01
Transplant 31 (4.5%) 17 (2.6%) 1.68 (0.91–3.13) 0.10 1.54 (0.81–2.52) 0.43
Obesity CMI$40 24 (4.8%) 4 (0.7%) 18.0 (2.40–134.8) 0.005 14.27 (1.67–91.7) 0.01
Previous antibiotic treatment 176 (25.4%) 74 (11.0%) 2.72 (1.99–3.72) ,0.001 1.84 (1.06–3.20) 0.03
Systemic corticosteroids 59 (8.5%) 23 (3.4%) 2.43 (1.46–4.04) 0.001 2.97 (1.01–8.76) 0.04
Inhaled corticosteroids 154 (22.2%) 69 (10.2%) 2,49(1,83–3,39) 0.000
Pandemic influenza vaccine
Children: 0–17 yrs 3 (1.8%) 0 (0.0%) 0.15 (0.01–2.88) 0.12 0.11 (0.03–2.34) 0.14
Adults: $18 yrs 9 (1.8%) 4 (0.8%) 1.75 (0.51–5.98) 0.37 1.14 (0.20–6.52) 0.88
Seasonal influenza vaccine
Children: 0–17 yrs 29 (17.5%) 26 (16.5%) 0.97 (0.54–1.74) 0.92 0.82 (0.41–1.64) 0.57
Adults: $18 yrs 103 (20.9%) 104 (22.4%) 0.84 (0.59–1.19) 0.33 0.70 (0.46–1.07) 0.1
Presence of risk factors
Moderate risk 314 (53.2%) 255 (41.2%) 3.21 (2.35–4.39) ,0.001 2.88 (1.90–4.35) ,0.001
High risk 148 (25.1%) 64 (10.3%) 6.86 (4.38–10.74) ,0.001 6.43 (3.45–11.98) ,0.001
Number of risk factors
No Risk factors 256(37.2%) 185(28.3%) 1 - 1 -
1 Risk factor 175 (25.4%) 195(28.3%) 1.35(1.04–1.75) 0.022 1.32 (1.00–1.76) 0.046
2 Risk factors 97 (14.1%) 63 (9.2%) 2.32(1.62–3.30) ,0.001 2.08 (1.41–3.07) ,0.001
$3 Risk factors 160 (23.3%) 44 (6.4%) 5.48(3.79–7.93) ,0.001 4.86(3.21–7.35) ,0.001
Crude and adjusted odds-ratios, from bivariate and multivariate (logistic regression) analyses respectively, are shown. Only variables used in the adjusted analyses are
reported.
OR=Odds ratio; CI=Confidence interval.
doi:10.1371/journal.pone.0033139.t003
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pandemic influenza infection in the global pooled analysis by Van
Kerkohve et al. [40].
These results largely confirmed previous reports on factors
associated to hospitalization in pandemic influenza virus-infected
patients. For instance, Jain et al. [23] identified asthma, COPD,
diabetes, immunosupression, chronic cardiovascular disease,
chronic renal disease, neurocognitive disorder, neuromuscular
disorder, pregnancy and seizure disorder as medical conditions
representing an increased risk for complications of pandemic
influenza infection. The more conditions present in any individual,
the higher the risk of complications leading to hospitalization,
especially for patients with 18 or more years of age. This was an
observational study of US-wide reported cases with 272 patients
evaluated from April 1 to June 9, 2009, during the initial
pandemic wave. Since no appropriate control group was analyzed,
the authors could not provide estimates of relative risk for these or
other factors frequently found among hospitalized patients. This
problem was overcome by Yu et al. [29] in their large study of
hospitalizations in China due to pandemic influenza by using as
control the general population and comparing serious (defined as
entrance in ICUs or death) and mild (other courses of the disease)
infections providing estimate of relative risks for both affected
groups. Similar factors to those of Jain et al. [23] were identified as
associated to serious progress of infection. An accumulation of
factors was also identified by the UK FLU-CIN [42] to confidently
differentiate between pandemic influenza and community ac-
quired pneumonia patients admitted to hospitals. In our analysis,
we have determined that both the number and the severity of risk
factors are positively associated to increased risk of hospitalization.
The presence of at least one high risk factor more than doubles the
risk of hospitalization compared to moderate factors (aOR 6.43
and 2.88, respectively). Similarly, the more risk factors present in a
patient, regardless their severity, the higher the risk of hospital-
ization (Table 3). Gilca et al. [22] also found that the presence of at
least one underlying medical condition increased significantly the
risk of hospitalization. The use of an appropriate matched control
group of pandemic influenza patients reinforces these conclusions
and the need to monitor closely the presence of these factors in
influenza infected patients.
Although slightly more than half (55%) of the cases were
included in the study after the launching of the vaccination
program with the pandemic formulation, the low coverage with
the pandemic vaccine, both in hospitalized and non-hospitalized
patients, is remarkable and precluded making any meaningful
comparison between the two groups because the statistical power
to detect differences was very low. Vaccination coverage with the
seasonal influenza vaccine was higher than that of the seasonal
influenza vaccine. It would have been reasonable for at least those
people vaccinated with the seasonal vaccine to have been
vaccinated with the pandemic vaccine, because the majority of
cases included in this study appeared once the pandemic vaccine
was available in Spain [43]. Possible communication failures on
the effectiveness of the vaccine and, especially, its safety [44–46],
may explain this.
Pregnancy was not a significant factor for hospitalization in our
study. Several previous reports have held the opposite. For
instance, Louie et al. [39] concluded that H1N1 influenza virus
could cause severe illness and death in pregnant and postpartum
women in California, but no control group or general cohort was
analyzed to establish relative risk or significance values for this
assertion. Among women who were hospitalized due to pandemic
influenza infection in the USA during 2009, pregnancy appeared
to be associated to severity of the infection and death [47] but,
once again, no control population was analyzed. Nevertheless, the
proportions of hospitalized pregnant women varied largely among
studies [48]. Our finding that women in the last weeks of
pregnancy do have an increased risk of hospitalization suggests
that a more detailed analysis of this factor should be undertaken.
This observational study may have some limitations. One
possible limitation is that interviewers knew whether interviewees
were cases or controls and this could have influenced information
gathering. However, the same protocol was followed for both
groups and information on vaccination history and clinical
variables was collected from medical records recorded before the
study began, so it is unlikely that information bias, if any, affected
the results. Another possible limitation is the generalization of our
conclusions, which are based on a relatively large but still limited
sample, to the general population. This is inherent to most case-
control studies, because this design severely reduces sample sizes as
compared to those based on population analysis. This potential
drawback is compensated, in our opinion, by the large number
hospitals and primary care centers involved in the study, which
provide a wide representation of the Spanish population.
For clinical physicians, and also for public health managers, it is
crucial to establish which factors are associated to severity of
influenza infection and to an increased need of hospitalization.
Differences in disease progression have multifactorial causes and
include biological (from both hosts and pathogens), social, and pre-
existing clinical conditions. Replacement of the previous H1N1
strain (Brisbane/59/07) by the new 2009 pandemic strain might
be accompanied by a change in progression and other clinical
effects, which have to be carefully studied. Some studies have
compared the relevant features of previous seasonal and the new
pandemic. For instance, Carcione et al. [49] found no relevant
differences in factors related to infection and hospitalization
between seasonal and pandemic influenza in Western Australia
during the 2009 influenza season, a period and place in which
both H1N1 strains co-circulated. For the Advisory Committee on
Immunization Practice of the United States CDC, persons
considered to be at high risk of infection by influenza A (H1N1)
virus strains differed between seasonal and pandemic viruses in
factors such as neurologic or neurodevelopment conditions, long-
term aspirin treatment (for persons aged ,=18 years), being of
American Indian or Alaska Native ethnicity, and being aged .65
years instead of 50 [4,50].
In conclusion, our results show that non-Caucasian ethnic
groups and people with low educational level have a higher risk of
being hospitalized if pandemic influenza virus infection occurs, as
also do people presenting three or more medical conditions. These
findings may help establishing which groups should receive special
attention when a new influenza virus appears in the human
population.
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